Baxdrostat: A Novel Aldosterone Synthase Inhibitor for Treatment Resistant Hypertension.
Publication/Presentation Date
7-1-2023
Abstract
Hypertension is a global epidemic, affecting around 30.4% of the population and being the leading preventable risk factor for death. Despite the availability of numerous antihypertensive agents, less than 20% of individuals have their blood pressure controlled. Resistant hypertension poses a challenge, but a new class of medication, aldosterone synthase inhibitors (ASI), shows promise. ASI reduces aldosterone production by inhibiting aldosterone synthase. This review article focuses on Baxdrostat, a highly potent ASI currently in phase 3 trials. It discusses the drug's biochemical pathway, efficacy trials in animals and humans, and its potential in uncontrolled hypertension, chronic kidney disease, and primary aldosteronism.
First Page
101918
Last Page
101918
ISSN
1535-6280
Published In/Presented At
Dogra, S., Shah, S., Gitzel, L., Puskar, B., Sood, A., Vyas, A. V., & Gupta, R. (2023). Baxdrostat: A Novel Aldosterone Synthase Inhibitor for Treatment Resistant Hypertension. Current problems in cardiology, 101918. Advance online publication. https://doi.org/10.1016/j.cpcardiol.2023.101918
Disciplines
Medicine and Health Sciences
PubMedID
37399857
Department(s)
Department of Medicine, Cardiology Division, Department of Medicine Fellows and Residents, Fellows and Residents
Document Type
Article